Tyler Robin is an Oncology physician affiliated with University of Colorado Anschutz Medical Campus. OpenAlex indexes 130 publications with 3,122 citations (h-index 23); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
Sponsor: University of Colorado, Denver
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
89%alpha-Adrenergic Blocker78.6%Tamsulosin Hcl91%Alfuzosin Hcl Er9%Part D<11 patientsbeta3-Adrenergic Agonist10.4%Myrbetriq100%Part D<11 patientsCancer & immunology
11%Gonadotropin Releasing Hormone Receptor Antagonist11%Orgovyx100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2012–2013 per NIH RePORTER. The latest:
- The Role of Eya3 as a downstream target of EWS Fli1 in Ewings Sarcoma
University of Colorado Denver
FY2013$23,307F30CA165873 - The Role of Eya3 as a downstream target of EWS Fli1 in Ewings Sarcoma
University of Colorado Denver
FY2012$28,126F30CA165873
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2025 - Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database
Urologic Oncology Seminars and Original Investigations
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Schulick, MD, MBA
University of Colorado Anschutz Medical Campus
John Rumsfeld, MD, PhD
University of Colorado Anschutz Medical Campus
Robert Eckel, MD
University of Colorado Anschutz Medical Campus
Marc Bonaca, MD
University of Colorado Anschutz Medical Campus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”